Related Experiment Video
Updated: Aug 6, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review
Abdulmajeed Abdulghani A Sindi1
1Department of Basic Medical Sciences, Faculty of Applied Medical Sciences, Al-Baha University, Al-Aqiq, Albaha, Saudi Arabia 65779-7738.
Insights
Newer PCSK9 inhibitors offer effective lipid-lowering for cardiovascular disease, especially for statin-intolerant patients. These injectable therapies show promise in reducing cardiovascular risk with manageable side effects.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Genetics
Background:
- Cardiovascular disease (CVD) poses a significant global health burden, with dyslipidemia being a key contributor.
- Statins are the primary therapy for hyperlipidemia, effectively lowering low-density lipoprotein cholesterol (LDL-C) and reducing CVD risk.
- However, statin intolerance and limitations in achieving target LDL-C levels necessitate alternative treatments.
Purpose of the Study:
- To review the genetics, safety, tolerability, and cost-effectiveness of PCSK9 inhibitors as alternatives to statins.
- To analyze the efficacy of PCSK9 inhibitors in specific patient subgroups based on recent clinical trials.
- To evaluate the potential of PCSK9 inhibitors in managing dyslipidemia and reducing cardiovascular mortality.
Main Methods:
- Narrative review of existing literature and data from randomized clinical trials (ORION, ODYSSEY, FOURIER).
- Analysis of genetic factors influencing PCSK9 inhibitor efficacy and immunogenicity.
- Assessment of safety profiles, tolerability, and lipid-lowering properties of evolocumab, alirocumab, and inclisiran.
Main Results:
- PCSK9 inhibitors demonstrate considerable lipid-lowering properties and are administered via subcutaneous injection.
- Evolocumab, alirocumab, and inclisiran show favorable profiles with minimal side effects and superior efficacy, particularly in statin-intolerant patients.
- While long-term cost-effectiveness is under investigation, current data suggest promising outcomes.
Conclusions:
- PCSK9 inhibitors represent a valuable therapeutic option for managing dyslipidemia and reducing cardiovascular risk.
- These agents offer an effective alternative for patients with statin intolerance or those not achieving LDL-C goals.
- Further research into long-term outcomes and cost-effectiveness will solidify their role in cardiovascular disease management.
Abstract:
Cardiovascular disease causes significant personal, financial, and societal burden and is a major cause of mortality and morbidity globally. Dyslipidemia has proven to be a major factor that contributes to its increased incidence; thus, since a long time, low-density lipoprotein cholesterol-lowering therapies have been employed to reduce coronary artery disease-associated mortality. The first-line therapy for hyperlipidemia and dyslipidemia is statins. Evidence showed that statins decrease the level of LDL-C resulting in a lower risk of CVD (20-25% for every decrease of 1 mmol/L). However, due to statin intolerance in some patients and despite using maximal doses, they have not been successful in lowering cardiovascular-associated mortality. Moreover, bococizumab was recently suspended due to its higher immunogenicity with time, resulting in less efficacy with long-term use. Alternatives to statins are PCSK9 inhibitors which are administered subcutaneously every two or four weeks. They are injectables with considerable lipid-lowering properties. This narrative review discusses their genetics, safety, tolerability, and cost-effectiveness. It also quantifies their benefit in certain subgroups by analyzing the findings from recent randomized clinical trials. Current data from phase 2 and 3 trials (ORION, ODYSSEY, and FOURIER) suggest a favorable profile for evolocumab, alirocumab, and inclisiran with minimal tolerable side effects and superior efficacy in statin-intolerant patients. Their cost-effectiveness has not yet been established clearly, but future outcomes seem promising.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:31Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:28Biopharmaceutics and Pharmacokinetics: Overview